@article{c3de84defef24575bde0eaadb8d1dd79,
title = "Toxicity Management of Systemic Kidney Cancer Therapies",
keywords = "Adverse events, Immune-related adverse events, Renal cell carcinoma, Toxicity management",
author = "Qian Qin and Ellen Nein and Andrea Flaten and Tian Zhang",
note = "Funding Information: Q Qin reports consulting for Exelixis and MJH Associates. T Zhang reports the following: Research funding: Novartis, Switzerland, Merck, United States, Regeneron, United States, Mirati Therapeutics, United States, Janssen, United States, AstraZeneca, Pfizer, United States, Astellas, Eli Lilly & Co, United States, and Tempus; Advisory/Consulting fees: Merck, Exelixis, Sanofi-Aventis, BMS, Janssen, Astra Zeneca, United States, Pfizer, Amgen, Pharmacyclics, SeaGen, QED Therapeutics, Eisai, Aveo, Eli Lilly, Bayer, Aravive, Caris, MJH Associates, Vaniam, Aptitude Health, and Peerview. E. Nein and A. Flaten have no disclosures.",
year = "2023",
month = oct,
doi = "10.1016/j.hoc.2023.05.006",
language = "English (US)",
volume = "37",
pages = "993--1003",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "5",
}